| Identification | Back Directory | [Name]
TAUROCHOLIC ACID | [CAS]
81-24-3 | [Synonyms]
C05122
Cholaic
taurocholate
Cholytaurine
aurocholicaci
cholyltaurine
n-choloyltaurine
TAUROCHOLIC ACID
n-choloyl-taurin
TAURODEOXYCHOLATE
TAURINE,N-CHOLOYL-
cholan-24-yl)amino)-
-oxocholan-24-yl]amino]-
cholicacidtaurineconjugate
Taurocholic Acid MaxSpec? Standard
3,7,12-Trihydroxy-5-cholan-24-oicacid24-taurineamide
2-[(3α,7α,12α-Trihydroxy-24-oxo-5β-cholan-24-yl)amino]ethanesulfonic acid
2-[[3α,7α,12α-Trihydroxy-24-oxo-5β-cholan-24-yl]amino]ethanesulfonic acid
5-BETA-CHOLANIC ACID-3-ALPHA, 7-ALPHA, 12-ALPHA-TRIOL N-(2-SULPHOETHYL)-AMIDE
ethanesulfonicacid,2-(((3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxo
2-((3-alpha,7-alpha,12-alpha-trihydroxy-24-oxo-5-beta-cholan-24-yl)amino)ethan
2-[[(3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]ethanesulphonic acid
2-((R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
2-[4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid | [EINECS(EC#)]
201-336-2 | [Molecular Formula]
C26H45NO7S | [MDL Number]
MFCD00053458 | [MOL File]
81-24-3.mol | [Molecular Weight]
515.7 |
| Hazard Information | Back Directory | [Chemical Properties]
Crystals. Stable in air. Freely soluble in water; soluble in alcohol,
almost insoluble in ether and ethyl acetate. | [Uses]
anti-inflammatory
| [Definition]
ChEBI: A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals. | [in vivo]
Taurocholic acid can induce stress-induced gastric injury models[3].
Induction of
stress-induced gastric injury[3] Background
Both in humans and experimental
animals, Taurocholic acid irritates the gastric mucosa and causes the reverse
diffusion of acid through the broken barrier[3].
Specific Modeling Methods
Rat: Donryu strain rats ? male ?
230-240 g &bull
Administration: 30-300 mg/kg ? p.o ? single
dose.
Note
After rats have fasted for 24 hours, their pylorus is ligated under ether anesthesia. Fifteen minutes after pylorus ligation, medication is administered to the rats.
The pylorus-ligated rats are then placed in cages with restricted movement.
Subsequently, the cages are immersed in a water bath maintained at 23°C until the water level reaches the xiphoid process of the rats, lasting for 7 hours.
Seven hours later, the animals are sacrificed under ether anesthesia, and the stomach of each animal is removed. The gastric contents are collected through the esophagus and analyzed for volume and acidity.
Modeling Indicators Molecular Changes: Significant reductions in acidity and pepsin activity were observed, along with an increase in Na+ concentration. However, there was no effect on gastric juice volume or K+ concentration.
Correlated Product(s): Aspirin (HY-14654) Opposite Product(s): L-Glutamine (HY-N0390) | Animal Model: | C57BL/6 mice[2] | | Dosage: | 100-mg/kg | | Administration: | oral gavage, for 2 weeks after tail vein injection with rAAV8-1.3HBV for 6 weeks | | Result: | Reduced the percentage of NK and CD3+CD8+ T cells.
Increases serum HBsAg, HBeAg, and HBV DNA levels.
|
| [IC 50]
Microbial Metabolite; Human Endogenous Metabolite | [storage]
Store at -20°C | [Purification Methods]
Crystallise the acid from EtOH/EtOAc/Et2O (amorphous m 125o) or EtOH/Et2O [Josephson Biochem J 29 1484 1935]. The sodium salt (hydrate) [312693-83-7, 345909-26-4 (xH2O)] crystallises from aqueous EtOH/Et2O with m 231-232o, [] D 23 +25.2o (c 1, H2O); and has max (H2SO4) at 303, 389 and 480nm. [Beilstein 10 III 2177, 10 IV 2078.] |
|
|